Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of American Medical Systems Holdings, Inc. (“AMS” or the “Company”) (NasdaqGS: AMMD) for potential breaches of fiduciary duties in connection with their duty to disclose material information in the Preliminary Proxy (“Proxy”) filed with the S.E.C. on April 22, 2011 related to the sale of the Company to Endo Pharmaceuticals Holdings Inc. (NasdaqGS: ENDP) for approximately $2.9 billion, including the assumption of debt. Furthermore, the price for the sale of AMS is also under investigation, which offers AMS shareholders $30 per share in cash in exchange for each AMS share they hold.
Request more information now by clicking here: www.faruqilaw.com/AMMD
Whether the AMS’ Board of Directors breached their fiduciary duties to AMS’ stockholders by failing to disclose all material information in the Proxy and whether it also failed to maximize shareholder value and if so by how much the sale undervalues the Company to the detriment of AMS shareholders, which are the key focus of this investigation.
Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.If you own common stock in AMS and wish to obtain additional information, please visit us at www.faruqilaw.com/AMMD or contact Juan E. Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330. Attorney Advertising. (C) 2011 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.